DEVELOPMENT AND EVALUATION OF MUCOADHESIVE NANOGEL OF NEVIRAPINE FOR VAGINAL APPLICATION by Rahman, Sheikh Sofiur & AHMED, ABDUL BAQUEE
 
 




SHEIKH SOFIUR RAHMAN*, ABDUL BAQUEE AHMED 
*
Received: 05 Feb 2019, Revised and Accepted: 28 Mar 2018 




Objective: The main objective of this study was to develop and evaluate Nevirapine nanoparticle loaded mucoadhesive gel (NVP-Np mucoadhesive 
gel) for vaginal application for the treatment of HIV infection. 
Methods: NVP loaded nanoparticles were prepared by salting out method followed by incorporation in different gel bases to produce NVP-Np 
mucoadhesive gel The prepared gels were evaluated for their physicochemical parameters, rheological characteristics, mucoadhesion, in vitro drug 
release and ex-vivo permeation of drug across porcine vaginal mucosa. 
Results: The result of FT-IR and DSC study confirmed the absence of incompatibility of NVP with excipients used in the formulations. The particle 
size of the prepared NVP-Np was found to be 243.8±3.15 nm, a polydispersity index (PI) of 0.787±0.002 and zeta potential value-17.12 mV, which 
revealed the stability of nanoparticles. All the formulations showed good homogeneity, spreadability, physical appearance and content uniformity. 
The pH of the mucoadhesive gel formulations was in the range of 3.70±0.03 to 4.56±0.02, which lies in the normal pH range of the vaginal fluid. The 
cumulative amounts permeated at 6 h were 832.23±63.45 μg/cm2, 592.13±82.55 μg/cm2 and 941.32±81.10 μg/cm2 from F1(1% Chitosan), F2(1% 
Carbopol 974P) and F3 (1% HPMC K100M) respectively. A linear relationship [r2
Conclusion: In conclusion, NVP-Np mucoadhesive gel was prepared successfully using salting out followed by a homogenization technique for 
vaginal application of NVP for the prophylaxis of HIV infection. 
>0.9 (0.97 n 0.99)] was observed between the percentage 
cumulative amount permeated and time, indicating zero order kinetics. 
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Public health, all over the world is facing a serious challenge as 
occurrences of HIV have become pandemic [1, 2]. A recent report 
states that 19 million out of 35 million HIV positive people are 
unaware that they have acquired the virus. Though there are no 
reports of new HIV infections in the past 10 y, still new methodologies 
for the prevention of HIV infections is the need of the hour [1]. 
The HIV pandemic has pushed researchers to explore the 
development of new preventive technologies. Data collected from 
the developing countries shows that the occurrence of HIV positive 
is 4 times higher in the case of women aged up to 24 y compared to a 
man of the same age group. In 2012, there were reports of 2 million 
new adult infections, especially young African women. Such fig. are 
mostly seen in developing countries and highlight the vulnerability 
of women to HIV infections. However, in most countries the use of 
condoms, (mostly men condom) is the only method to control HIV 
infection, women cannot insist to use it. Moreover, women who want 
to conceive cannot use condoms [3]. 
As revised, elsewhere rings gels films and creams are typical vaginal 
dosage forms with advantages for particular drugs and particular 
indications [4]. The development of nanoparticles based vaginal 
drug delivery mainly focused on pre-exposure prophylaxis. 
Nanoparticles can provide sustained release of microbicide drugs, 
which is necessary for maintaining protective drug concentrations 
between the time of dosing and the time of intercourse. Drug release 
from nanoparticles can result in more controlled vaginal absorption 
compared to a drug depot like a vaginal gel, thereby potentially 
requiring reduced amounts of the drug. Nanoparticles can be 
designed to contain multiple modalities, to target specific cells, and 
to have intrinsic antimicrobial activity [4]. 
NVP, chemically known as 1-cyclopropyl-5,11-dihydro-4-methyl-6H-
dipyrido [3,2-b: 2',3'-e] [1, 4] diazepine-6-one is a non-nucleoside 
reverse transcriptase inhibitor, active against herpes simplex virus 
type 1 and 2 and against varicella zoster virus1-2. It is a potent non-
nucleoside reverse transcriptase inhibitor used in combination with 
nucleoside analogues for the treatment of HIV infection and AIDS. 
NVP binds directly to reverse transcriptase and blocks the RNA-
dependent and DNA-dependent DNA polymerase activities by 
causing a disruption of the enzyme's catalytic site. The activity of 
NVP does not compete with template or nucleoside. The most 
common adverse effect of NVP is the development of mild or 
moderate rash (13%) [5]. 
Mucoadhesive nanogels have gained greater attention as an 
alternative to conventional gels in the last decade. Mucoadhesive 
nanogels are easier to handle and administer than conventional gels 
due to their lesser viscosity in room temperature. On the other hand, 
the high viscosity of the nanogels at body temperature can minimize 
chances of gel leakage. Hence developing a mucoadhesive nanogel of 
NVP may increase the residence time of the formulation and to 
rapidly penetrate through vaginal mucus in order to deliver the drug 
to the vaginal epithelium and thereby expected to improve the 
therapeutic effectiveness of the NVP in the vaginal cavity. Thus, the 
main objective of this study was to develop and evaluate Nevirapine 
nanoparticle loaded mucoadhesive gel (NVP-Np mucoadhesive gel) 
for vaginal application for the treatment of HIV infection. 
MATERIALS AND METHODS 
NVP was obtained from Astrix Laboratories Limited (Hyderabad, 
India) Chitosan was purchased from Sigma–Aldrich (Denmark) 
Polyvinyl alcohol (PVA), Carbopol 974P, Carboxymethyl cellulose 
(CMC), HPMC K100M, methylparaben and MgCl2 were purchased 
from Sigma–Aldrich (Denmark). All chemicals and solvents used in 
this study were of analytical Grade. HPLC-grade acetonitrile, 
methanol, potassium phthalate and ammonium acetate were 
purchased from Sigma (Denmark). Glacial acetic acid (purity 99.8%) 
was obtained from Merck (Darmstadt, Germany). Phosphate buffer 
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solution (pH 4.5) was prepared by mixing appropriate amounts of 
ammonium acetate and acetic acid. 
Drug-excipient compatibility study 
Fourier Transform-Infrared (FT-IR) spectroscopy and Differential 
Scanning Calorimetry (DSC) was performed to determine the drug-
excipient compatibility. FT-IR analysis has been performed using a 
sample of NVP with various excipients at 1:1 mass/mass ratio used 
in the formulation. FT-IR spectra were recorded on a Bruker 
spectrophotometer (Model-220, Germany) in the range of 4000–400 
cm-1
NVP-Np were prepared by salting out the method [6]. In brief, 200 
mg of NVP and 30 mg of chitosan were dissolved in 30 ml of acetone 
at room temperature for 2 h. The organic phase was then 
incorporated into 70 ml of saturated aqueous solution of polyvinyl 
alcohol under magnetic stirring to form an o/w emulsion. The 
resulting emulsion was stirred at 1000 rpm for 1 h and subsequently 
homogenized at 24,000 rpm for 5 min using a high-speed 
homogenizer (IKA T25 digital Ultra Turrax, Germany). To this 
emulsion, water was added with constant stirring to facilitate 
diffusion and finally evaporate the organic solvent. This resulted in 
polymer precipitation and formation of nanoparticles. Free drug and 
surfactant were separated by centrifugation (REMI cooling 
centrifuge, Vasai) at 10,000-×g for 20 min. 
 [9, 10]. 
A differential scanning calorimeter (Jade DSC, Perkin Elmer, USA) was 
used for thermal analysis of NVP and NVP-excipients mixtures. 
Individual samples (NVP and excipients) as well as physical mixtures 
of NVP and selected excipients (all passed through a 60-mesh sieve) 
were weighed directly in the pierced DSC aluminium pan and scanned 
in the temperature range of 20–300 °C under an atmosphere of dry 
nitrogen. The heating rate of 10 °C/min was used and thermograms 
obtained were observed for any interaction [10, 11]. 
Fabrication and evaluation of NVP loaded nanoparticles 
The particle size and the PI of the prepared nanoparticles were 
measured immediately by dynamic laser light scattering method at 
25 °C at a scattering angle of 90 ° using Zetasizer Nano ZS 90 
(Malvern Instruments Ltd. UK). The zeta potential of the 
preparations was also measured using the clear disposable Zeta cell 
for zeta potential analysis by electrophoretic mobility method 
(Zetasizer ZS 90; Malvern Instruments Ltd. UK) [7, 8].  
Preparation and evaluation of NVP-Np based mucoadhesive gel  
The prepared NVP-Np was incorporated into three different types of 
mucoadhesive gel. Each of which contains different types of a 
mucoadhesive polymer such a Carbopol 974P, Chitosan and HPMC 
K100M respectively. Weighed quantity (1% w/w) each of Carbopol 
974P and HPMC K100M were dispersed separately in water. Chitosan 
(1% w/w) was dispersed in the glacial acetic acid (GAA) solution. The 
dispersions were stirred for 2–3 h. NVP-Np (equivalent to 0.2% w/w of 
NVP) was incorporated into each gel base. Glycerol and methylparaben 
(MP) were added to the formulations as humectants and preservative 
respectively with continuous magnetic stirring until a homogeneous 
dispersion was formed. The dispersion was then neutralized and made 
viscous by the addition of triethanolamine. The compositions of different 
mucoadhesive gel formations are listed in (table 1). 
 
Table 1: Formulations composition of NVP-Np based mucoadhesive gel 










F1 0.2 1 -- -- -- 0.5 10 
F2 0.2 -- 1 -- 15 -- 10 
F3 0.2 -- -- 1 0.5 -- 10 
 
Evaluation of NVP-Np based mucoadhesive gel 
Physical appearance and spreadability 
The physical appearance and homogeneity of the prepared gels were 
tested by visual observations [12]. The spreadability of the gel 
formulations was determined at 24 h after dissolution, by measuring 
the spreading diameter of 1 g of gel between two horizontal plates 
(20 cm × 20 cm) after one min. The standardized weight tied on the 
upper plate was 125 g [13].  
Measurement of pH, drug content and viscosity 
The pH values of the gel formulations were determined by using a 
pH meter (Schott CG 840, Germany) at room temperature 24 h after 
preparation, and discarding air bubbles. The measurement was 
performed at 1, 30 and 60 d after preparation to detect any pH 
fluctuation with time [14]. 
For assay of the drug in gels, NVP was extracted from 1 g of each gel 
formulations with 20 ml of methanol for 30 min. The resultant mixture 
was filtered through a membrane filter (pore size 0.45 mm). The 
absorbance of the sample was determined spectrophotometrically at 
230 nm (Shimadzu UV-1800, Japan) after appropriate dilution with an 
aqueous solution of phosphate buffer pH 4.5. The concentration of NVP 
was estimated from the regression equation of the calibration curve.  
The viscosity of the gel formulations was determined using 
Brookfield viscometer (Brookfield DV-III+Rheometer TC-502 
Temperature Controller, USA) with spindle no. 64 at 10 r. p. m at the 
temperature of 30 °C. 
Determination of texture profile analysis 
Texture profile analyses of the gels were evaluated using Texture 
Analyzer (TA. XT. Plus Texture Analyzer, Stable Micro Systems, 
London, UK) equipped with 5 kg load cell in texture profile analysis 
(TPA) mode. An analytical probe of 1.2 cm in diameter was 
depressed twice into each sample to a fixed depth (15 mm), at a 
defined rate (30 mm/min), with a defined recovery period (15 s), 
between the end of the first compression and the beginning of the 
second. A trigger force of 4 g was applied. At least six replicate 
analyses of each sample were performed at 37 °C. Data collection 
and evaluation were done by Texture pro software, version 4.0. 
Based on the resultant force-time plot, mechanical parameters such 
as hardness, compressibility, adhesiveness, cohesiveness and 
elasticity of the gel formulations were determined [15]. 
Mucoadhesion studies 
The experimental procedure used to determine the mucoadhesion of 
the different vaginal gel was reported. Mucoadhesion testing of 
different gels was carried out using a texture analyzer (TA. XT. Plus 
Texture Analyzer, Stable Micro Systems, London, UK) with a 50N 
load cell equipped with a mucoadhesive holder. Freshly excised 
porcine vaginal mucosa was frozen at −20  °C. A 2 mm thick section 
was taken from the inner part of the surface of the frozen vaginal 
mucosa and attached to the lower end of the probe of the instrument 
with cyanoacrylate glue. The mucosa was dipped into the phosphate 
buffer and kept for 10 min prior to the commencement of the 
experiment. Instrumental parameters (table 2) were used to study 
the mucoadhesive potential of vaginal gel formulations. 
In vitro drug release study 
The in vitro drug release from NVP-Np based mucoadhesive gel was 
performed across cellulose membranes by using Keshary-Chien 
diffusion cell [16] with an effective diffusional surface area of 1.54 
cm2 and a receptor cell volume of 20 ml. The receptor compartment 
was filled with the solution of phosphate buffer solution pH 4.5 and 
maintained at 37±5 °C with constant magnetic stirring. 1g of the gel 
was placed on the donor compartment and covered with a piece of 
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aluminium foil to prevent drying out. The samples (1 ml) were 
collected from the receptor compartment at the predetermined time 
interval for 6 h period and replaced by an equal volume of fresh 
prewarmed receptor solution to maintain constant volume allowing 
sink condition throughout the experiment. The amounts of NVP in 
the samples were determined by HPLC analysis. 
 
Table 2: Testing conditions and instrumental parameters of texture analyzer utilized in the evaluation of the mucoadhesive potential of 
vaginal gel formulations 
Experimental parameter Experimental setup 
Immersion fluid Phosphate buffer (pH 4.5) 
Test temperature 37 
Probe speed (mm/s) 1 
Probe force(N) 0.2 
Mucosa contact time(s) 150 
 
HPLC analysis of NVP 
HPLC analysis of NVP was quantified in samples using high-performance 
liquid chromatography (HPLC). The HPLC system consisted of a Dual 
pump (Model M515, Waters Corp., Milford, MA, USA) and UV-Visible 
detector (Model M2489, Waters Corp., USA) set at a wavelength of 230 
nm. The samples were chromatographed on a reverse-phase NOVA-PAK 
HR C18 column (4 μm, 150 × 3.9 mm i.d.), (Waters Corp., USA). A mixture 
of methanol, acetonitrile and buffered solution at pH 3.0 with 
orthophosphoric acid at 20:20:60 ratios, respectively, was used as the 
mobile phase. The mobile phase was filtered through a 0.45-μm 
membrane filter and degassed under vacuum and was pumped at a flow 
rate of 1 ml/min for the runtime of 10 min, under these experimental 
conditions 20 μl of the sample solution was injected by Rheodyne 
Injector (Model 7725i, Waters Corp., USA). The column was 
thermostated at ambient temperature (40 °C) (Eunice et al., 2005). The 
above-mentioned method was validated for specificity, intra-day and 
inter-day accuracy, precision, and linearity 
Ex-vivo permeation study 
This study was carried out using porcine vaginal mucosa because 
porcine vaginal mucosa seems good in vitro permeability model for 
human vaginal mucosa [17]. The vaginal tissue was collected from 
the local slaughterhouse (Azara, Guwahati, India) and was frozen by 
placing them in containers with a phosphate buffer saline pH 4.5 
(PBS) mixtures and stored at-20 °C until use. Prior to the 
experiment, frozen porcine vaginal tissue specimens were thawed in 
Krebs solution for 1 h at 37◦C. Subsequently, the vaginal tissues 
were dermatomed at a thickness of 300±50 µm and mounted on the 
Keshary-Chien diffusion cell with an effective diffusional surface 
area of 1.54 cm2 and a receptor cell volume of 20 ml. The receptor 
compartment was filled with the PBS solution at 37 °C with constant 
magnetic stirring. 1g of nanogel formulations was placed on the 
donor compartment and covered with a piece of aluminium foil to 
prevent drying out. The samples (1 ml) were collected from the 
receptor compartment at the predetermined time interval for 8 h 
period and replaced by an equal volume of fresh prewarmed 
receptor solution to maintain constant volume allowing sink 
condition throughout the experiment [18]. The amounts of NVP in 
the samples were determined by HPLC. Apparent permeability 
coefficient (Papp
P
) values were calculated from permeability data 
according to the following equation [19].  
app




 ………… (3) 
2
Data and statistical analysis 
), C the initial concentration of drug in the donor 
compartment (µg/ml) and t the total time of the experiment(s). 
The steady state flux (J,μg/cm2/h) was calculated from the slope of the 
linear plot of the cumulative amount permeated per unit area 
(μg/cm2) as a function of time (t,h). The permeability coefficient (Papp, 
cm2
Data are represented as mean±SD (n = 3). Statistical comparisons 
were made using Student is 
/S) was calculated from the flux and donor drug concentration. 
t-test at a significance level of p<0.05 using MS Excel software. 
Stability study 
For stability study, the F1, F2 and F3 formulations were tightly 
packed in the aluminium collapsible tube (5 g) and stored at 25 
°C/60 % relative humidity (RH) and 40 °C/75% RH for a period of 3 
mo in a stability chamber (REMI, Environmental Test Chamber, 
India). Samples were withdrawn in duplicate at 0 and after 1, 2, and 
3 mo, and their physical and chemical stabilities were inspected. 
Physical stability was evaluated by visual observation for physical 
appearance, pH, and rheological properties. Chemical stability was 
calculated as NVP content, which was determined through HPLC 
analysis [20, 21]  
RESULTS AND DISCUSSION 
Drug-excipient compatibility study 
FT-IR and DSC carried out an analysis of drug-excipients 
compatibility study. The FT-IR spectra (fig. 1) of NVP showed 
characteristics band at 1643.70 cm−1 for (C=O stretching, 
aromatic/cyclic amide); 1464.56 cm−1 (C=C stretching, aromatic), 
1410.03 cm−1 (skeletal vibration stretching), 1288.24 cm−1 (C-N, 
stretching), 1209.63 cm−1 (C-H in-plane bending), 2950 cm−1
The DSC curve of NVP showed a first endothermic event between 
240 and 250 °C (fig. 3) with a melting temperature of (T
(N-H 
peak) [22]. These entire characteristics band for NVP were also 
retained in 1:1 physical mixture of various NVP-excipients mixture 
(fig. 2). The results indicated the absence of interaction, which was 
further supported by DSC study [23]. 
onset 
Physico-chemical characterization of NVP loaded nanoparticles 
= 245.58 
°C). This endothermic peak was also retained in all the mixture of 
drug-excipients with a little shifting of the peaks which may be due 
to the presence of moisture or impurity of the excipient. 
The particle size of the prepared NVP-Np was found to be 
243.8±3.15 nm with a low PI of 0.787±0.002. The low value of PI 
revealed uniform size distribution of particles. The zeta potential 
value of NVP-Np was found to be-17.12 mV. The net negative surface 
charge of the formulations may be due to the use cationic 
polyelectrolyte (Chitosan) and the addition of polyvinyl alcohol in 
the formulation aids to reduce aggregation of nanoparticles may 
indicate the good stability of the formulations [24].  
Physico-chemical properties of NVP-Np based mucoadhesive gel 
The results of the physicochemical test of NVP-Np based 
mucoadhesive gel were shown in (table 3). The results revealed that 
all the mucoadhesive gel showed good homogeneity, spreadability 
and physical appearance was observed as white or opaque in nature. 
The drug content in the gel was found to be 86.93±5.23 to 
91.23±6.35 %, showing content uniformity. The pH of the 
mucoadhesive gel formulations was in the range of 3.70±0.03 to 
4.56±0.02, which lies in the normal pH range of the vaginal fluid and 
would not produce any irritation in the vaginal cavity. There was no 
significant change observed in pH values (varied from 0.01 to 0.16) 
as a function of time for all formulations. The viscosity of the 
semisolid dosage form reflects the consistency of the product. The 
measured value of viscosity was found for F1 (1% w/w Chitosan), 
F2 (1% Carbopol 974P) and F3 (1% HPMC K100M) as 8123 cps, 
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8525 cps and 7379 cps respectively. The mucoadhesive gel 
formulations can be ranked according to their viscosity values as 
follows: F2 (viscosity 8525 cps)>F1 (viscosity 8123 cps)>F2 
(viscosity 7379 cps). Thus, the results of the physicochemical 




Fig. 1: FT-IR spectra of NVP, chitosan, chitosan+NVP 
 
 
Fig. 2: FT-IR spectra of NVP, NVP+carbopol 974P, NVP+HPMC K100M 
 
 
Fig. 3: DSC thermogram of NVP, NVP±Chitosan, NVP+Carbopol 974P 
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Table 3: Physicochemical evaluation of NVP-Np based mucoadhesive gel 
F. Code Spreading diameter after 1 min %NVP content  Physical appearance Homogeneity pH  
F1 54 88.86±4.22 Opaque Homogeneous 3.70±0.03 
F2 61 86.93±5.23 Opaque Homogeneous 4.09±0.04 
F3 49 91.23±6.35 White Homogeneous 4.56±0.02 
Data presented as mean±SD, n=3 
 
Table 4: Release parameters of NVP from NVP-Np based mucoadhesive gel across cellulose membrane 
F. Code Amount release at 6 h (µg/cm2 Release rate(µg/cm) 2 The best-fit regression equation for release rate plot /h) r2 
F1 987.32±7.32 164.63±21.31 12.66 t-1.4079 0.9924 
F2 696.34±8.01 116.08±26.43 11.298t-0.5139 0.9898 
F3 1042.01±6.92 173.07±21.92 13.29 t+3.5543 0.9905 
Data presented as mean±SD, n=3 
 
 
Fig. 4: Comparative permeation profiles of NVP from different NVP-Np based mucoadhesive gel across porcine vaginal mucosa. Data 
presented as mean±SD (n= 3) 
 
HPLC method validation 
The developed method was showed to be intra-assay and inter-
assay accuracy. The accuracy range was found at 86.70% to 95.09% 
for intra-assay and 96.10% to 99.10% for inter-assay respectively. 
The precision of the method was ascertained by the low value of % 
RSD (% Relative standard deviation) and % CV (% Coefficient 
variation). The value of % RSD and % CV were found in the range of 
0.5%-3.15% and 0.62%-3.44% respectively indicates the precision 
of the method. The retention time of the NVP was found to be 4.5 
min. A linear regression equation of y = 0.7927x-0.0157 (r2
The experiments for in vitro release of NVP from mucoadhesive gel 
formulations through cellulose membrane were performed in 
phosphate buffer solution pH 4.5. The release parameter is stated in 
(table 4). It has been observed that the total amount of drug release 
at 6 h was found to be 80.62 %, 70.68 and 84.94 % for formulations 
F1, F2 and F3 respectively. The release of the drug was found to be 
dependent on the nature of the polymer and their consistency. A 
faster release rate was observed from the gel formulation containing 
1% HPMC K100M (F3) than gel formulation contains 1% Chitosan 
(F1) and 1% Carbopol 974P (F2). At low concentration, HPMC 
K100M swells quickly and forms a less viscous gel due to the 
hydrophilic nature and fast hydration. On the other hands, Chitosan 
(F1) and Carbopol 974P (F2) gel showed a comparatively slower 
release rate of the drug due to the formation of a thicker gel which 
increases the diffusion path length of the drug. Drug release was 
significantly dependent on polymer type, and release profiles can be 
ranked in the following order: >HPMCK100M (F3) Chitosan 
(F1)>Carbopol 974P (F2) and the release of the drug was found to 
be inversely proportional to the viscosity of the gel formulations. 
The viscosity for F1, F2 and F3 were found to be 8123 cps, 8525 cps 
and 7393 cps. A linear relationship [r
 = 
0.9998) across the full range of concentrations from 30–90 μg/ml 
was obtained for NVP. The lower limit of quantification was 
observed as 10 µg/ml. 
In vitro evaluation 
2
Values of mucoadhesive strengths of the gels are also displayed in 
(table 5); The mucoadhesive strength for F1, F2 and F3 gels was 
16.26±0.86 g, 19.35±0.85 and 13.22±1.05 g respectively. 
>0.9 (0.98-0.99)] was 
obtained between the amount released and the time as proposed by 
the zero order release theory (10), indicating the diffusion 
controlled mechanism of drug release. 
Mucoadhesion test evaluation 
The present study determines the various mechanical properties as 
well as mucoadhesive strengths of the gels with the help of Texture 
Analyser, Stable Micro Systems, London, UK. Results of the texture 
profile analysis and mucoadhesive strengths are tabulated in (table 
5). The hardness of Chitosan gel (F1), Carbopol 974P (F2) and HPMC 
K100M (F3) was ranged from 13.22±1.05, 19.55±0.86 g and 16.26-
±1.86 g respectively. 
Values of adhesiveness of F1, F2 and F3 gels varies from 
0.062±0.003 g to 0.016±0.001 g. The cohesiveness of F1 gels was 
0.99±0.03. For F2 and F3, it varies from 1.01±0.04 to 1.10±0.03. 
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Table 5: Values of texture profile analysis and mucoadhesive strength of conventional gels 
Formulation code Hardness(g) Adhesiveness(g) Cohesiveness Mucoadhesive strength(g) 
F1 28.03±0.32 0.016±0.001 0.99±0.03 16.26±0.85 
F2 38.32±0.65 0.062±0.003 1.01±0.04 19.35±0.86 
F3 21.01±1.13 0.008±0.002 1.10±0.03 13.22±1.05 
Data presented as mean±SD (n=3) 
 
Ex vivo permeation evaluation 
The results of ex vivo vaginal permeation of NVP from gels across 
porcine vagina have been shown in (fig. 4). The vaginal permeation 
profile showed the same pattern as that of the in vitro release profile 
across the cellulose membrane. The cumulative amounts permeated 
at 6 h were 832.23±63.45, 592.13±82.55 and 941.32±81.10 μg/cm2 
from the gel formulations containing 1% Chitosan (F1), 1% Carbopol 
974P (F2), 1% HPMC K100M (F3) respectively. A linear relationship 
[r2>0.9 (0.97 n 0.99)] was observed between the cumulative amount 
permeated and time, indicating zero order kinetics. The apparent 
permeability coefficient for F1, F2, F3 was found 122.71±4.1, 
107.63±2.3 and 185.43±6.8 ml cm-2h-1 respectively. The highest 
steady state flux was observed in F3 formulation (156.63±10.91 
(µg/cm2/h) and lowest was found in F2 (98.13±8.31(µg/cm2
CONCLUSION 
/h) 
formulation. The flux of different formulations may be compared as 
F3>F1>F2 which suggest an inverse relationship between 
permeation rate and the viscosity of the gel formulation.  
Stability study 
The results of stability studies revealed that the F1, F2, F3 
formulations were stable at both the storage conditions in terms of 
physical and chemical properties. No significant change was observed 
for physical appearances, pH, and viscosity. The drug content of the 
formulation before stability and after stability study were found to be 
88.86±4.22%,86.93±5.23%, 91.23±6.35 % and 87.89±3.02, 
86.11±4.34%, 90.93±1.12% respectively, revealed no significant 
chemical change in the formulation after 3 mo of the stability study. 
In conclusion, NVP-Np mucoadhesive gel was prepared successfully 
using salting out followed by homogenization technique. NVP-Np 
mucoadhesive gel containing 1% each of Chitosan (F1), Carbopol 
974P (F2) and HPMC K100M (F3) showed good physicochemical 
characteristics with high permeation of NVP across porcine vaginal 
mucosa. Amongst all the formulations F3 showed better 
physicochemical characteristics such as viscosity 7393cps, 
mucoadhesion strength 16.26±1.86g, pH 4.56±0.02 with good 
permeation rate 156.63±10.91µg/cm2
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